References
- Crawford NP, Colliver DW, Galandiuk S. Tumor markers and colorectal cancer: Utility in management. J Surg Oncol 2003;84:239–48.
- Keyomarsi K, Tucker SL, Buchholz TA, Callister M, Ding Y, Hortobagyi GN, . Cyclin E and survival in patients with breast cancer. N Engl J Med 2002;347:1566–75.
- Akli S, Zheng PJ, Multani AS, Wingate HF, Pathak S, Zhang N, . Tumor-specific low molecular weight forms of cyclin E induce genomic instability and resistance to p21, p27, and antiestrogens in breast cancer. Cancer Res 2004;64:3198–208.
- Resnitzky D, Gossen M, Bujard H, Reed SI. Acceleration of the G1/S phase transition by expression of cyclins D1 and E with an inducible system. Mol Cell Biol 1994;14:1669–79.
- Cassia R, Moreno-Bueno G, Rodriguez-Perales S, Hardisson D, Cigudosa JC, Palacios J. Cyclin E gene (CCNE) amplification and hCDC4 mutations in endometrial carcinoma. J Pathol 2003;201:589–95.
- Bloom J, Pagano M. Deregulated degradation of the cdk inhibitor p27 and malignant transformation. Semin Cancer Biol 2003;13:41–7.
- Strohmaier H, Spruck CH, Kaiser P, Won KA, Sangfelt O, Reed SI. Human F-box protein hCdc4 targets cyclin E for proteolysis and is mutated in a breast cancer cell line. Nature 2001;413(6853):316–22.
- Rajagopalan H, Jallepalli PV, Rago C, Velculescu VE, Kinzler KW, Vogelstein B, . Inactivation of hCDC4 can cause chromosomal instability. Nature 2004;428(6978):77–81.
- Porter DC, Zhang N, Danes C, McGahren MJ, Harwell RM, Faruki S, . Tumor-specific proteolytic processing of cyclin E generates hyperactive lower-molecular-weight forms. Mol Cell Biol 2001;21:6254–69.
- Wingate H, Bedrosian I, Akli S, Keyomarsi K. The low molecular weight (LMW) isoforms of cyclin E deregulate the cell cycle of mammary epithelial cells. Cell Cycle 2003;2:461–6.
- Bedrosian I, Lu KH, Verschraegen C, Keyomarsi K. Cyclin E deregulation alters the biologic properties of ovarian cancer cells. Oncogene 2004;23:2648–57.
- Milne AN, Carvalho R, Jansen M, Kranenbarg EK, van de Velde CJ, Morsink FM, . Cyclin E low molecular weight isoforms occur commonly in early-onset gastric cancer and independently predict survival. J Clin Pathol 2008;61:311–6.
- Corin I, Di Giacomo MC, Lastella P, Bagnulo R, Guanti G, Simone C. Tumor-specific hyperactive low-molecular-weight cyclin E isoforms detection and characterization in non-metastatic colorectal tumors. Cancer Biol Ther 2006;5:198–203.
- Hur K, Kim JR, Yoon BI, Lee JK, Choi JH, Oh GT, . Overexpression of cyclin D1 and cyclin E in 1,2-dimethylhydrazine dihydrochloride-induced rat colon carcinogenesis. J Vet Sci 2000;1:121–6.
- Yasui W, Kuniyasu H, Yokozaki H, Semba S, Shimamoto F, Tahara E. Expression of cyclin E in colorectal adenomas and adenocarcinomas: Correlation with expression of Ki-67 antigen and p53 protein. Virchows Arch 1996;429:13–9.
- Sutter T, Doi S, Carnevale KA, Arber N, Weinstein IB. Expression of cyclins D1 and E in human colon adenocarcinomas. J Med 1997;28:285–309.
- Feng M, Pei F, Yang G, Mao Z, Wang S. Expression of p53 and p21 protein in transitional mucosa adjacent to rectal carcinoma and its clinical implication. J Tongji Med Univ 2000;20:220–1.
- Chen LC, Hao CY, Chiu YS, Wong P, Melnick JS, Brotman M, . Alteration of gene expression in normal-appearing colon mucosa of APC(min) mice and human cancer patients. Cancer Res 2004;64:3694–700.
- Libertini SJ, Robinson BS, Dhillon NK, Glick D, George M, Dandekar S, . Cyclin E both regulates and is regulated by calpain 2, a protease associated with metastatic breast cancer phenotype. Cancer Res 2005;65:10700–8.
- Bales E, Mills L, Milam N, McGahren-Murray M, Bandyopadhyay D, Chen D, . The low molecular weight cyclin E isoforms augment angiogenesis and metastasis of human melanoma cells in vivo. Cancer Res 2005;65:692–7.
- Akli S, Van Pelt CS, Bui T, Multani AS, Chang S, Johnson D, . Overexpression of the low molecular weight cyclin E in transgenic mice induces metastatic mammary carcinomas through the disruption of the ARF-p53 pathway. Cancer Res 2007;67:7212–22.
- Lim YJ, Kim YH, Ahn GH, Chun HK, Jang WY, Lee JH, . Cyclin E, p27 and mutant p53 do not predict the prognosis in AJCC stage II colorectal carcinomas. Korean J Gastroenterol 2004;44:314–20.